Core Points - The company Shanghai Kangdelai Enterprise Development Group Co., Ltd. has recently obtained the property rights certificate for a land parcel in Jiading District, Shanghai, which it acquired through an online auction on December 14, 2021 [1] - The land parcel, located at No. 587, Gaochao Road, Jiading District, has a total area of 15,080.10 square meters and a building area of 46,624.68 square meters [1] - The land is designated for research and design purposes, with a usage period from December 21, 2021, to December 20, 2071 [1]

康德莱（603987）在2025年上海辖区上市公司集体接待日暨中报业绩说明会活动上回答投资者提问称， 本次协议转让系引入战略投资股东，目前相关事项正常推进中。 ...

Group 1 - The company, Shanghai Kangdai Enterprise Development Group Co., Ltd., will participate in the 2025 Shanghai Listed Companies Collective Reception Day and Mid-Year Performance Briefing [1] - The event will be held online on September 19, 2025, from 15:00 to 17:00, allowing investors to engage with company executives regarding the company's mid-year performance, governance, development strategy, and operational status [1][2] - Investors can submit questions for discussion until 14:00 on the same day through a designated webpage, ensuring that the interaction is relevant and focused on investor concerns [1]

证券代码：603987 证券简称：康德莱 公告编号：2025-023 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路 演 APP，参与本次互动交流。 活动时间为 2025 年 9 月 19 日（周五）15:00-17:00。届时公司高管将在线 就公司 2025 半年度业绩、公司治理、发展战略、经营状况等投资者关心的问题， 与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 为充分尊重投资者，提升交流的针对性，投资者可于 2025 年 9 月 19 日（周 五）14:00 前访问 http://ir.p5w.net/zj/进入问题征集专题页面。公司将在本 次集体接待日上，对投资者普遍关注的问题进行回答。 特此公告。 （问题征集专题页面二维码） 上海康德莱企业发展集团股份有限公司董事会 2025 年 9 月 13 日 上海康德莱企业发展集团股份有限公司 关于参加 2025 年上海辖区上市公司集体接待日暨中报业绩说明 会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈 ...

证券代码：603987 证券简称：康德莱 公告编号：2025-022 上海康德莱企业发展集团股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 (五) 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事9人，出席6人，董事长张宪淼先生，董事、副总经理张勇先生， 因工作原因无法出席会议；独立董事郭超先生因个人原因无法出席会议； 2、 公司在任监事3人，出席3人； (一) 股东会召开的时间：2025 年 9 月 11 日 (二) 股东会召开的地点：上海市嘉定区高潮路 658 号会议室 3、 董事会秘书顾佳俊女士出席了本次会议，财务总监沈晓如先生列席了本次会 议。 一、 会议召开和出席情况 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 660 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 178,621,295 | | 3、出席会议 ...

德恒上海律师事务所 关于 上海康德莱企业发展集团股份有限公司 2025 年第一次临时股东会之 见证意见 上海市东大名路 501 号上海白玉兰广场办公楼 23 层 电话：021-55989888/55989666 传真：021-5598 9898 邮编：200080 德恒上海律师事务所 关于上海康德莱企业发展集团股份有限公司 2025 年第一次临时股东会之见证意见 关于上海康德莱企业发展集团股份有限公司 2025 年第一次临时股东会之 见证意见 德恒 02G20170018-00034 号 致：上海康德莱企业发展集团股份有限公司 德恒上海律师事务所接受上海康德莱企业发展集团股份有限公司（以下或称 "公司"）的委托，指派本所见证律师对公司于 2025 年 9 月 11 日 10:00 召开的 2025 年第一次临时股东会（以下简称"本次股东会"）进行见证并出具本见证 意见。 本所见证律师依据本见证意见出具日前已经发生或存在的事实和《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"） 等现行有效的法律、法规和 ...

Core Viewpoint - Kangdelai (603987.SH) has introduced a strategic investor, Changsha Medical Investment Co., Ltd., to enhance its competitive position and valuation in the healthcare industry through a share transfer of 21.84 million shares, representing 5% of the total share capital [1][4]. Group 1: Share Transfer Details - Kangdelai's controlling shareholder, Kangdelai Group, will transfer 21.84 million shares to Changsha Medical Investment at a price of 10.81 yuan per share, which is a 16.24% premium over the market closing price on the announcement date, totaling approximately 236 million yuan [2][4]. - Following the transaction, Changsha Medical's stake in Kangdelai will increase from 1.45% to 6.45% [4][5]. Group 2: Financial Performance - In the first half of 2025, Kangdelai reported revenue of 1.125 billion yuan, a year-on-year increase of 0.17%, with a net profit of 125 million yuan, up 18.94% [2][9]. - The company's operating costs decreased by 3.37% to 757 million yuan, contributing to an improved gross margin of 32.66%, which is an increase of 2.47 percentage points year-on-year [10][9]. Group 3: Strategic Goals - The share transfer aims to deepen Kangdelai Group's strategic layout and promote collaborative synergies, enhancing market competitiveness and optimizing corporate governance [5][6]. - Kangdelai plans to leverage the strategic partnership to expand its presence in the consumer healthcare sector and improve its overall business structure [5][6]. Group 4: Industry Position and R&D - Kangdelai is one of the few companies in China with a complete medical puncture device industry chain, focusing on integrated manufacturing and regional operational advantages [8]. - In the first half of 2025, Kangdelai invested 51.67 million yuan in R&D, accounting for 4.59% of its revenue, and achieved significant product registrations and certifications [11].

Core Viewpoint - Kangdelai (603987.SH) has introduced a strategic investor, Changsha Medical, to enhance its competitive position and valuation in the medical device industry through a share transfer of 21.84 million shares, representing 5% of the total share capital [2][4]. Group 1: Strategic Investment - Kangdelai's controlling shareholder, Kangdelai Group, plans to transfer 21.84 million shares to Changsha Medical at a price of 10.81 yuan per share, which is a 16.24% premium over the market price on the announcement date, totaling approximately 236 million yuan [2][4]. - After the transaction, Changsha Medical's stake in Kangdelai will increase to 6.45% from 1.45% [5][6]. Group 2: Financial Performance - In the first half of 2025, Kangdelai reported revenue of 1.125 billion yuan, a year-on-year increase of 0.17%, and a net profit of 125 million yuan, up 18.94% [3][7]. - The company's operating costs decreased by 3.37% to 757 million yuan, while the gross profit margin improved by 2.47 percentage points to 32.66% [8]. Group 3: Business Strategy and Development - Kangdelai focuses on integrating its medical device production capabilities and optimizing its product structure to enhance its competitive edge and profitability [8][9]. - The company has established four manufacturing bases across Shanghai, Zhejiang, Guangdong, and Guangxi, leveraging regional advantages to achieve cost efficiency and scale [8]. Group 4: Research and Development - In the first half of 2025, Kangdelai invested 51.67 million yuan in R&D, accounting for 4.59% of its revenue, and completed registrations for six new products [9].

Core Viewpoint - The strategic share transfer agreement between Shanghai Kangdelai and Changsha Medical Investment marks a significant step towards the company's transformation into a "medical + consumer" integration model, aiming to enhance market competitiveness and optimize governance structure [1][3]. Company Overview - Kangdelai is a leading enterprise in the domestic medical puncture instrument industry, with main products including medical puncture needles, infusion instruments, and interventional instruments [2]. - The company has faced challenges due to intensified competition and profit margin compression from centralized procurement policies in the medical device sector [2]. Financial Performance - Sales revenue for Kangdelai's core puncture care products is projected to decline, with expected revenues of 1.786 billion yuan and 1.607 billion yuan for 2023 and 2024, respectively, reflecting year-on-year decreases of 8.07% and 10.03% [2]. - In the first half of 2025, Kangdelai reported a slight revenue increase to 1.125 billion yuan, a year-on-year growth of 0.17%, with net profit reaching 125 million yuan, up 18.94% [2]. Strategic Initiatives - To explore new growth opportunities, Kangdelai is focusing on the consumer medical sector, planning to invest in new products and diverse business models [2]. - The company aims to integrate resources and identify promising new industry projects in the medical and consumer fields to drive future growth [2]. Strategic Partnership - The acquisition of a 5% stake by Changsha Medical Investment, a subsidiary of Kefu Medical Technology, is seen as a strategic move that will enhance Kangdelai's market position and governance [1][3]. - Kefu Medical is a prominent player in the consumer medical device market, which may provide Kangdelai with additional resources and synergies [2].

Group 1: 恒瑞医药 - Company received approval for clinical trials of HRS-7172 tablets, a new anti-tumor small molecule inhibitor [1] - Subsidiary received approval for SHR-A2009, an antibody-drug conjugate targeting HER3 [1] - Company was established in April 1997, focusing on drug research, production, and sales [1] Group 2: 康德莱 - Controlling shareholder plans to transfer 5% of shares to strategic investor at a price of 10.81 yuan per share, totaling 236 million yuan [1] - Post-transfer, controlling shareholder's stake will decrease from 39.58% to 34.58% [1] - Company was established in July 1998, specializing in medical devices [2] Group 3: 中钢洛耐 - Shareholder plans to reduce holdings by up to 1% of total shares due to fund exit needs [3] - Company was established in August 2006, focusing on high-end refractory materials [3] Group 4: 瑞玛精密 - Subsidiary completed acquisition of land in Mexico for production operations, covering 52,300 square meters at a price of 3.4064 million USD [4] - Company was established in March 2012, specializing in precision metal stamping and related products [4] Group 5: 鸿博股份 - Company confirmed normal operations despite stock price fluctuations exceeding 20% over three trading days [5] - Company was established in June 1999, focusing on lottery services and high-end packaging [6] Group 6: 东芯股份 - Company completed stock trading risk investigation and resumed trading [7] - Company was established in November 2014, specializing in storage chip design and sales [7] Group 7: 凯迪股份 - Company stated that its robot products are still in development and will not generate revenue in the short term [8] - Company was established in August 1992, focusing on linear drive systems [8] Group 8: 诺唯赞 - Major shareholder plans to reduce holdings by up to 3% due to funding needs [9] - Company was established in March 2012, focusing on functional proteins and organic materials [9] Group 9: 君实生物 - Company received approval for clinical trials of JT118 injection, a "two-in-one" recombinant protein vaccine for monkeypox [10] - Company was established in December 2012, focusing on new drug research and related services [10] Group 10: 赛力斯 - Company reported August sales of 45,818 vehicles, with a 19.57% increase in new energy vehicle sales [11] - Company was established in September 2012, focusing on automotive research and sales [11] Group 11: 燕东微 - Major shareholder plans to reduce holdings by up to 1% due to management needs [13] - Company was established in October 1987, focusing on semiconductor products and services [13] Group 12: 中百集团 - Company reported cumulative litigation and arbitration amounts of approximately 262 million yuan over the past 12 months [14] - Company was established in January 1990, focusing on retail business [14] Group 13: 金开新能 - Company received 939 million yuan in renewable energy subsidies, with a 341.67% increase year-on-year [15] - Company was established in March 1997, focusing on renewable energy development and operation [15] Group 14: *ST天茂 - Company plans to terminate stock listing and initiate cash option mechanism for shareholders [16] - Company was established in November 1993, focusing on various insurance services [16] Group 15: 宁德时代 - Company repurchased 8.69 million A-shares for a total of 2.131 billion yuan [17] - Company was established in December 2011, focusing on battery research and production [17] Group 16: 山西高速 - Controlling shareholder plans to increase holdings by 30 to 60 million yuan [18] - Company was established in February 1996, focusing on highway management [18] Group 17: 青岛银行 - Major shareholder plans to increase holdings by 233 to 291 million shares [19] - Company was established in November 1996, focusing on banking services [19] Group 18: 格力电器 - Major shareholder completed share increase of 46.38 million shares for 2.099 billion yuan [20] - Company was established in December 1989, focusing on air conditioning production and sales [20] Group 19: 中国石油 - Company plans to transfer 541 million A-shares to China Mobile Group to enhance strategic cooperation [21] - Company was established in November 1999, focusing on oil and gas exploration and production [21] Group 20: 镇洋发展 - Company announced a merger plan with Zhejiang Huhangyong Highway Co., with a share exchange ratio of 1:1.08 [22] - Company was established in December 2004, focusing on chemical products [22]